<DOC>
	<DOCNO>NCT00807755</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , carboplatin etoposide , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) together everolimus may kill tumor cell . PURPOSE : This phase I trial study side effect best dose everolimus , carboplatin , etoposide treat patient small cell lung cancer advance solid tumor .</brief_summary>
	<brief_title>Everolimus , Carboplatin , Etoposide Treating Patients With Small Cell Lung Cancer Other Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility everolimus combine carboplatin etoposide patient advance solid tumor , emphasis small cell lung cancer ( SCLC ) . Secondary - Determine maximum-tolerated dose regimen patient . - Describe dose-limiting toxicity toxicity profile associate regimen patient . - Determine , preliminarily , efficacy regimen expand cohort patient SCLC . - Assess pharmacokinetic parameter everolimus combination . OUTLINE : This dose-escalation study . Patients receive oral everolimus day 1-21 , carboplatin IV 15-30 minute day 1 , etoposide IV 30 minute day 1-3 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients expand cohort undergo blood collection day 1 , 15 , 22 pharmacokinetic study liquid chromatography-tandem mass spectrometry . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor curative standard treatment available Ten additional patient extensive stage small cell lung cancer accrue expand cohort maximum tolerate dose ( dose exploration ) determine Must chemotherapy naive Measurable evaluable disease Prior irradiate disease site consider measurable clear disease progression follow radiation therapy No uncontrolled brain leptomeningeal metastasis ( include require glucocorticoid ) PATIENT CHARACTERISTICS : Zubrod performance status 02 Life expectancy &gt; 3 month Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.3 mg/dL OR creatinine clearance &gt; 40 mL/min Serum bilirubin ≤ 1.5 mg/dL ( regardless liver involvement ) SGOT ≤ 3 time upper limit normal ( ULN ) INR ≤ 1.3 ( ≤ 3 anticoagulation ) Fasting serum cholesterol ≤ 300 mg/dL* Fasting triglycerides ≤ 2.5 time ULN* No severe and/or uncontrolled medical comorbidities condition could affect participation study include , limited , follow : Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤ 6 month prior first study treatment Serious uncontrolled cardiac arrhythmia Severely impaired lung function Active ( acute chronic ) uncontrolled infection Nonmalignant medical illness uncontrolled control may jeopardize study therapy Liver disease ( i.e. , cirrhosis , chronic active hepatitis , chronic persistent hepatitis ) No uncontrolled diabetes mellitus ( i.e. , fast serum glucose &gt; 1.5 time ULN ) No HIV seropositivity Not pregnant nursing Fertile patient must use effective contraception No oral , implantable , injectable contraceptives No impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) No active , bleed diathesis No known hypersensitivity everolimus rapamycins ( e.g. , sirolimus , temsirolimus ) excipients Must able take retain oral medication No peripheral neuropathy &gt; grade 1 per NCI CTCAE vs. 3 NOTE : *In case one threshold exceed , patient include initiation appropriate lipidlowering medication . PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy More 3 week since prior concurrent investigational drug At least 3 week since prior chemotherapy At least 2 week since prior major surgery completion radiotherapy No immunization attenuate live vaccine within past week study therapy No prior treatment mTOR inhibitor ( e.g. , sirolimus , temsirolimus , everolimus ) No chronic treatment systemic steroid immunosuppressive agent No concurrent oral antivitamin K medication ( except low dose coumadin ) No concurrent medication interfere everolimus No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>